TR200103804T2 - Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler - Google Patents

Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler

Info

Publication number
TR200103804T2
TR200103804T2 TR2001/03804T TR200103804T TR200103804T2 TR 200103804 T2 TR200103804 T2 TR 200103804T2 TR 2001/03804 T TR2001/03804 T TR 2001/03804T TR 200103804 T TR200103804 T TR 200103804T TR 200103804 T2 TR200103804 T2 TR 200103804T2
Authority
TR
Turkey
Prior art keywords
formula
replication
inhibit
substances
respiratory syncytial
Prior art date
Application number
TR2001/03804T
Other languages
English (en)
Inventor
Eduard Janssens Frans
Petrus Marie-Jos Meersman Kathleen
Maria Sommen Fran�ois
Emile Georges Guillemont Jer�me
Fernend Armand Lacrampe Jean
Jozef Lodewijk Marcel Andries Koenraad
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of TR200103804T2 publication Critical patent/TR200103804T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bu bulus, formül (I)e sahip bilesiklerin, virütik enfeksiyonlari, özellikle RSV enfeksiyonlarini tedavi etmeye mahsus bir ilaç üretiminde kullanimi ile ilgili olup; burada -a1=a2-a3=a4, -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH- veya -CH=CH-CH=N- formüle sahip bir radikaldir ve buradaki her bir hidrojen atomu, istege bagli olarak subsititüe edilebilir;Q,(b-1), (b-2), (b-3), (b-4), (b-5), (b-6), (b-7) ve (b-8) formülüne sahip bir radikaldir, G,bir dogrudan bag veya C1-10 alkandiildir;R1, istege bagli olarak sübstitüe edilmis bir monosiklik bir heterohalkadir.Formül (I)e sahip bazi bilesikler yenidir.
TR2001/03804T 1999-06-28 2000-06-20 Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler TR200103804T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99202087 1999-06-28
EP00200452 2000-02-11

Publications (1)

Publication Number Publication Date
TR200103804T2 true TR200103804T2 (tr) 2002-05-21

Family

ID=26071821

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2001/03804T TR200103804T2 (tr) 1999-06-28 2000-06-20 Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler
TR2006/00172T TR200600172T2 (tr) 1999-06-28 2000-06-20 Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2006/00172T TR200600172T2 (tr) 1999-06-28 2000-06-20 Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler.

Country Status (38)

Country Link
US (5) US6924287B1 (tr)
EP (2) EP1418175A1 (tr)
JP (1) JP2003503401A (tr)
KR (1) KR100731276B1 (tr)
CN (1) CN1239496C (tr)
AP (1) AP1552A (tr)
AR (1) AR030152A1 (tr)
AT (1) ATE276244T1 (tr)
AU (1) AU779516B2 (tr)
BG (1) BG65372B1 (tr)
BR (1) BR0012054A (tr)
CA (1) CA2376781A1 (tr)
CO (1) CO5190695A1 (tr)
CZ (1) CZ20014574A3 (tr)
DE (1) DE60013836T2 (tr)
DK (1) DK1196408T3 (tr)
EA (1) EA004939B1 (tr)
EE (1) EE04590B1 (tr)
EG (1) EG24026A (tr)
ES (1) ES2228559T3 (tr)
HK (1) HK1046141B (tr)
HR (1) HRP20010933A2 (tr)
HU (1) HUP0201723A3 (tr)
IL (2) IL147326A0 (tr)
MX (1) MXPA02000112A (tr)
MY (1) MY135747A (tr)
NO (1) NO324036B1 (tr)
NZ (1) NZ515418A (tr)
OA (1) OA11978A (tr)
PL (1) PL198021B1 (tr)
PT (1) PT1196408E (tr)
SA (1) SA01220400A (tr)
SG (1) SG122814A1 (tr)
SI (1) SI1196408T1 (tr)
SK (1) SK18942001A3 (tr)
TR (2) TR200103804T2 (tr)
TW (1) TWI248932B (tr)
WO (1) WO2001000611A1 (tr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495580B1 (en) 1998-01-29 2002-12-17 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
EP1418175A1 (en) * 1999-06-28 2004-05-12 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
US6506738B1 (en) 2000-09-27 2003-01-14 Bristol-Myers Squibb Company Benzimidazolone antiviral agents
US6774134B2 (en) 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
US7030150B2 (en) * 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
US6919331B2 (en) 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
WO2003059289A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
WO2003060475A2 (en) * 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
EP1539691A2 (en) 2002-08-09 2005-06-15 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
US8202896B2 (en) 2002-08-09 2012-06-19 Microdose Therapeutx, Inc. Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
BR0314595A (pt) 2002-09-20 2005-08-09 Arrow Therapeutics Ltd Uso de um derivado de benzodiazepina ou um sal farmaceuticamente aceitável deste, inalador ou nebulisador, produto, usos de um produto e de um composto ou sal farmaceuticamente aceitável deste, derivado de benzodiazepina, composto, e, composição farmacêutica
WO2005021547A2 (en) * 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
WO2005042530A1 (en) 2003-10-30 2005-05-12 Boehringer Ingelheim (Canada) Ltd. Rsv polymerase inhibitors
KR101187441B1 (ko) * 2003-12-18 2012-10-02 얀센 알 앤드 디 아일랜드 호흡기 세포융합 바이러스 복제의 억제제인아미노벤지미다졸 및 벤지미다졸
MXPA06007110A (es) * 2003-12-18 2006-08-23 Tibotec Pharm Ltd Derivados de los amino-bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio.
AR046959A1 (es) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
AR046972A1 (es) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd Derivados de los amino-bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
AR046770A1 (es) * 2003-12-18 2005-12-21 Tibotec Pharm Ltd Derivados bencimidazol 5- o 6-substituidos como inhibidores de la replicacion del virus sincitial respiratorio
ATE435222T1 (de) * 2003-12-18 2009-07-15 Tibotec Pharm Ltd Aminobenzimidazole und benzimidazole als inhibitoren der replikation von respiratory syncytial virus
TWI349007B (en) 2003-12-18 2011-09-21 Tibotec Pharm Ltd Piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
AU2006204750C1 (en) * 2005-01-14 2012-11-01 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US20060223849A1 (en) 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
RU2410382C2 (ru) * 2005-03-17 2011-01-27 Тиботек Фармасьютикалз Лтд 1, 3-дигидробензимидазол-2-илиденовые амины в качестве ингибиторов репликации респираторного синцитиального вируса
TWI370820B (en) * 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
PL1896450T3 (pl) * 2005-06-20 2013-01-31 Janssen Sciences Ireland Uc 2-podstawione benzimidazole
MX2007016311A (es) * 2005-06-20 2008-03-07 Tibotec Pharm Ltd Bencimidazoles sustituidos con heterociclilaminoalquilo.
AU2006260969B2 (en) 2005-06-20 2011-11-17 Janssen Sciences Ireland Uc 1- ( 2-amino-3- (substituted alkyl)-3H-benzimidazolylmethyl) -3-substituted-1,3-dihydro-benzoimidazol-2-ones with activity on respiratory syncytial virus
CA2622592A1 (en) 2005-09-19 2007-03-29 Arrow Therapeutics Limited Benzodiazepine derivatives for treating hepatitis c infection
MX2008012413A (es) 2006-03-29 2008-10-07 Hoffmann La Roche Derivados de piridina y pirimidina como antagonistas del receptor metabotropico de glutamato 2 (mglur2).
CA2692761C (en) 2007-07-12 2013-04-30 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation
MX2011008674A (es) * 2009-02-18 2011-11-04 Amgen Inc Compuestos de indol/bencimidazol como inhibidores de quinasa mtor.
CA2758961A1 (en) 2009-04-27 2010-11-04 High Point Pharmaceuticals, Llc Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as .beta.-secretase inhibitors
US8450354B2 (en) 2010-03-23 2013-05-28 High Point Pharmaceuticals, Llc Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as β-secretase inhibitors
TWI501967B (zh) * 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI530495B (zh) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
TWI527814B (zh) * 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI541241B (zh) 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
GB201119538D0 (en) 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
CA2873920C (en) 2012-06-15 2021-07-20 Janssen R&D Ireland 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
RU2015102537A (ru) * 2012-06-28 2016-08-20 Эббви Инк. Цианогуанидины и их применение в качестве противовирусных средств
MD20150071A2 (ro) 2013-02-19 2016-02-29 Pfizer Inc. Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
EA031201B1 (ru) 2014-08-06 2018-11-30 Пфайзер Инк. Соединения имидазопиридазина
GB201417707D0 (en) * 2014-10-07 2014-11-19 Viral Ltd Pharmaceutical compounds
WO2016094361A1 (en) * 2014-12-10 2016-06-16 Southern Research Institute Antiviral agents
IL294410B2 (en) 2016-11-23 2024-02-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
MX386699B (es) 2017-10-11 2025-03-19 Chemocentryx Inc Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2
KR20210079278A (ko) 2018-09-06 2021-06-29 시다라 세라퓨틱스, 인코포레이티드 바이러스 감염의 치료를 위한 조성물 및 방법
TWI861205B (zh) 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法
JP2022547538A (ja) * 2019-09-09 2022-11-14 シダラ セラピューティクス インコーポレーテッド 呼吸器合胞体ウイルス感染症の処置のための組成物及び方法
JP2023528969A (ja) 2020-06-11 2023-07-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 3-({5-クロロ-1-[3-(メチルスルホニル)プロピル]-1H-インドール-2 イル}メチル)-1-(2,2,2-トリフルオロエチル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]ピリジン-2-オンのヘミ(L)-酒石酸塩形態及びそれを含む医薬組成物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1140119A (en) * 1978-04-03 1983-01-25 Joseph Torremans N-heterocyclyl-4-piperidinamines
NO155805C (no) * 1981-02-06 1987-06-10 Ucb Sa Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter.
US4556660A (en) * 1982-07-12 1985-12-03 Janssen Pharmaceutica N.V. N-(Bicyclic heterocyclyl)-4-piperidinamines
US4634704A (en) 1983-10-06 1987-01-06 Janssen Pharmaceutica, N.V. Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines
US4695569A (en) * 1983-11-30 1987-09-22 Janssen Pharmaceutica N.V. Bicyclic heterocyclyl containing N-(bicyclic heterocyclyl)-4-piperidinamines
EP0144101B1 (en) * 1983-11-30 1991-02-06 Janssen Pharmaceutica N.V. Bicyclic heterocyclyl containing n-(bicyclic heterocyclyl)-4-piperidinamines
US4588722A (en) 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
PH23995A (en) * 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
ES2052544T3 (es) 1986-02-03 1994-07-16 Janssen Pharmaceutica Nv Composiciones anti-histaminicas que contienen n-heterociclil-4-piperidinaminas.
JPS62212386A (ja) * 1986-03-14 1987-09-18 Suntory Ltd 2−ピリジルメチルベンズイミダゾ−ル誘導体
US4897401A (en) * 1987-06-19 1990-01-30 Janssen Pharmaceutical N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives useful in treating allergic diseases
US4988689A (en) * 1987-07-01 1991-01-29 Janssen Pharmaceutica N.V. ((Pharmacologically active bicyclic heterocyclic)methyl and -heteroatom) substituted hexahydro-1H-azepines and pyrrolidines
CA1317939C (en) * 1987-07-01 1993-05-18 Janssen Pharmaceutica Naamloze Vennootschap ¬(bicyclic heterocyclyl)methyl and -hetero| substituted hexahydro-1h-azepines and pyrrolidines
GB8716313D0 (en) * 1987-07-10 1987-08-19 Janssen Pharmaceutica Nv 2-(heterocyclylalkyl)imidazopyridines
IT1226100B (it) * 1988-07-07 1990-12-10 Dompe Farmaceutici Spa Derivati benzimidazolici farmacologicamente attivi.
PH30434A (en) * 1989-04-07 1997-05-09 Janssen Pharmaceutica Nv Hydroxyalkylfuranyl derivatives
NZ238863A (en) * 1990-07-19 1993-03-26 Janssen Pharmaceutica Nv Substituted thiazolyl and pyridinyl derivatives
KR100190299B1 (ko) * 1990-07-19 1999-06-01 디르크 반테 신규한 옥사졸릴 유도체
US5360807A (en) * 1990-07-19 1994-11-01 Janssen Pharmaceutica N.V. Substituted thiazolyl and substituted pyridinyl derivatives
US5693661A (en) 1995-06-07 1997-12-02 Eli Lilly And Company Anti-viral compounds
US5998439A (en) * 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
PE107598A1 (es) 1996-09-11 1999-01-29 Ucb Sa Cetirizina util para el tratamiento de enfermedades de tipo virico
WO1998031363A1 (en) 1997-01-22 1998-07-23 Eli Lilly And Company Anti-viral compounds
EP1001767A4 (en) 1997-06-04 2001-07-04 Lilly Co Eli ANTIVIRAL CONNECTIONS
FR2772573B1 (fr) * 1997-12-18 2000-03-10 Manuf Ind Nouvelle Elements Sa Meuble sous evier depliable
EP1418175A1 (en) * 1999-06-28 2004-05-12 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
MXPA02000120A (es) * 1999-06-28 2002-07-02 Janssen Pharmaceutica Nv Inhibidores de la replicacion del virus sincitial respiratorio.
US6340681B1 (en) * 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists

Also Published As

Publication number Publication date
SA01220400A (ar) 2005-12-03
BR0012054A (pt) 2002-03-19
OA11978A (en) 2006-04-18
BG106287A (en) 2002-10-31
CZ20014574A3 (cs) 2002-05-15
PL362890A1 (en) 2004-11-02
AP2002002397A0 (en) 2002-03-31
EA200200087A1 (ru) 2002-08-29
KR100731276B1 (ko) 2007-06-21
CA2376781A1 (en) 2001-01-04
JP2003503401A (ja) 2003-01-28
AU779516B2 (en) 2005-01-27
NZ515418A (en) 2003-11-28
US7390811B2 (en) 2008-06-24
CO5190695A1 (es) 2002-08-29
NO20016368L (no) 2002-02-28
CN1239496C (zh) 2006-02-01
AP1552A (en) 2006-01-17
US20050239771A1 (en) 2005-10-27
IL147326A0 (en) 2002-08-14
US6924287B1 (en) 2005-08-02
HK1046141B (zh) 2006-09-22
US7173034B2 (en) 2007-02-06
BG65372B1 (bg) 2008-04-30
ATE276244T1 (de) 2004-10-15
TR200600172T2 (tr) 2007-10-22
EG24026A (en) 2008-03-26
SG122814A1 (en) 2006-06-29
NO324036B1 (no) 2007-07-30
DE60013836D1 (de) 2004-10-21
EP1196408B1 (en) 2004-09-15
SI1196408T1 (en) 2005-02-28
EE200100692A (et) 2003-02-17
US20060154913A1 (en) 2006-07-13
DK1196408T3 (da) 2005-01-24
US20050234047A1 (en) 2005-10-20
AR030152A1 (es) 2003-08-13
TWI248932B (en) 2006-02-11
KR20020005054A (ko) 2002-01-16
EP1196408A1 (en) 2002-04-17
ES2228559T3 (es) 2005-04-16
HUP0201723A3 (en) 2004-04-28
IL147326A (en) 2007-03-08
NO20016368D0 (no) 2001-12-27
TR200600172T1 (tr) 2007-01-22
US7173054B2 (en) 2007-02-06
PT1196408E (pt) 2005-01-31
HRP20010933A2 (en) 2003-06-30
DE60013836T2 (de) 2006-01-19
HK1046141A1 (en) 2002-12-27
WO2001000611A1 (en) 2001-01-04
AU5816700A (en) 2001-01-31
EE04590B1 (et) 2006-02-15
CN1358180A (zh) 2002-07-10
EA004939B1 (ru) 2004-10-28
EP1418175A1 (en) 2004-05-12
MXPA02000112A (es) 2002-07-02
US7361657B2 (en) 2008-04-22
HUP0201723A2 (hu) 2002-11-28
SK18942001A3 (sk) 2002-10-08
US20070021410A1 (en) 2007-01-25
MY135747A (en) 2008-06-30
PL198021B1 (pl) 2008-05-30

Similar Documents

Publication Publication Date Title
TR200600172T2 (tr) Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler.
TR200500707T2 (tr) Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler.
DE69427289D1 (de) Naphtalinderivate
TR200003383T2 (tr) HIV ve diğer virüs enfeksiyonlarının tedavisine yönelik bileşimler.
WO2006086445A8 (en) Combination therapy
TR200901979T2 (tr) Antikolinerjik etkili bileşik ve ?-mimetikler bazında yeni ilaç bileşimleri.
TR200003635T2 (tr) Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
TR200102780T2 (tr) Büyüme hormonu sekretagogları olarak yarar gösteren heterosiklik aromatik bileşikler
NO20000157L (no) Sammensetning og fremgangsmÕte ved behandling av penil erektil dysfunksjon
BR9811482A (pt) Derivados de 1-(n-fenilaminoalquil)-piperazina substituìda na posição 2 do anel fenìlico
CA2124206A1 (en) Indole derivatives
ATE254927T1 (de) Antagonisten der endothelinwirkung
EA200802329A1 (ru) Производные триазола ii
PE20011074A1 (es) Uso de pramipexol en el tratamiento de trastornos de adiccion
PE59199A1 (es) Derivados de hidroxamato invertido como inhibidores de la metaloproteasa de matriz, inhibidores de la metaloproteasa, e inhibidores del tnf-alfa
NO20000151L (no) Nitrogenoksid inhiberer rhinovirus infeksjon
BR0013625A (pt) Composição para uso no tratamento de carcinoma hepatocelular
ATE46332T1 (de) Spiro-imidazolidine als aldose-reduktaseinhibitoren.
KR940703666A (ko) 발기 부전증 치료에 효능있는 약제(a potent drug for treatment of erectile dysfunction)
KR910015300A (ko) 부스피론 : 수면 무호흡증의 치료용도
Newman et al. Blunted pulmonary pressor responses to hypoxia in blood perfused, ventilated lungs isolated from oxygen toxic rats: possible role of prostaglandins
RU2008129782A (ru) Противовирусное соединение
TR200001926T2 (tr) Vasküler başağrılarına karşı lokal anesteziklerin yeni kullanımı
CO6341549A2 (es) Combinacion coccidicida para uso veterinario
KR920011490A (ko) 척추 손상으로 인한 반사이상항진 치료용 3-아릴-5-알킬티오-4h-1, 2, 4-트리아졸